Abstract
Although psoriasis does not require any diagnostic laboratory tests, physicians need to keep in mind the variety of laboratory studies for both screening as well as ongoing monitoring of psoriasis therapies. A multitude of laboratory tests exists to examine the safety of these therapies, including topical therapies, phototherapy, oral medications, and/or biologic agents. Knowledge of the available tests is important to screen vulnerable selected populations prior to initiating psoriasis treatment, such as pregnant women, immunocompromised patients, or patients with certain medical conditions. Screening labs are important in identifying these patients. Most importantly, familiarity with the available laboratory studies will ensure timely management of any anticipated side effects of the various psoriasis therapies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Enamandram M, Kimball AB. Psoriasis epidemiology: the interplay of genes and the environment. J Invest Dermatol. 2013;133(2):287–9.
Mease PJ, et al. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2014;71:649–55.
Gottlieb A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851–64.
Armstrong AW, et al. Infectious, oncologic, and autoimmune comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting. J Rheumatol. 2013;40(8):1438–41.
Armstrong AW, et al. Cardiovascular comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting. J Rheumatol. 2013;40(8):1434–7.
Menter A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–50.
Menter A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–59.
Menter A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62(1):114–35.
Menter A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–85.
Hsu S, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148(1):95–102.
Helliwell PS, Taylor WJ, Group CS. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs – comparison of drugs and adverse reactions. J Rheumatol. 2008;35(3):472–6.
Lebwohl M, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008;58(1):94–105.
Expert Panel on Detection, E. and A. Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.
Sheridan S, Pignone M, Donahue K. Screening for high blood pressure: a review of evidence for the U.S. Preventative Services Task Force. Am J Prev Med. 2003;25(2):151–158.
Kavanaugh A, van der Heijde D, Beutler A, et al. Patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy demonstrate less radiographic progression: Results through 5 years of the randomized, placebo-controlled, GO-REVEAL study. Arthritis Care Res. 2015. doi: 10.1002/acr.22576. [Epub ahead of print].
Stuart PE, et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet. 2010;42(11):1000–4.
Trembath RC, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6(5):813–20.
Nair RP, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78(5):827–51.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Florek, A., Armstrong, A.W. (2016). Relevant Laboratory Tests and Therapeutic Monitoring in Psoriasis. In: Adebajo, A., Boehncke, WH., Gladman, D., Mease, P. (eds) Psoriatic Arthritis and Psoriasis. Springer, Cham. https://doi.org/10.1007/978-3-319-19530-8_23
Download citation
DOI: https://doi.org/10.1007/978-3-319-19530-8_23
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-19529-2
Online ISBN: 978-3-319-19530-8
eBook Packages: MedicineMedicine (R0)